Cytosar-U / Cytarabine: Overview

Modified on 2009/10/14 21:43 by admin
Cytosar-U, also known as Cytarabine, is indicated for the treatment of acute non-lymphocytic leukemia in adults and pediatric patients. Administered intravenously, through a shot under the skin of the arm or thigh (subcutaneous), or through a shot in a large muscle in a patient's buttocks, thigh, or upper arm (intramuscular), Cytosar-U interferes with cancerous cell growth, a characteristic of leukemia. The medication is made by Pharmacia & Upjohn. The U.S. Food and Drug Administration (FDA) approved Cytosar-U in 1969.

Side effects of Cytosar-U use include, but may not be limited to, loss of appetite, stomach cramps, a mild to severe rash, difficulty breathing, hair loss, yellowing of the skin and eyes, nausea and diarrhea. A black box warning on Cytosar-U's packaging label indicates that only a trained physician experienced in cancer chemotherapy medications should administer Cytosar-U. Toxic effects of Cytosar-U use include anemia, leukopenia and thrombocytopenia. A doctor is advised to weigh the benefits of Cytosar-U against its known toxic effects before prescribing the medication.

If you have experienced serious health problems after taking Cytosar-U, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Cancer Drugs: Overview
  2. Anemia
  3. Diarrhea: Overview
  4. Hair Loss: Overview
  5. Lung & Airway Disorders
  6. Nausea: Overview
  Name Size